239 related articles for article (PubMed ID: 26656794)
1. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.
Becker JP; Weiss J; Theile D
Toxicol Lett; 2014 Feb; 225(1):43-7. PubMed ID: 24275384
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
4. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
5. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
6. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
7. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
8. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
11. A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin.
Picone D; Donnarumma F; Ferraro G; Gotte G; Fagagnini A; Butera G; Donadelli M; Merlino A
J Inorg Biochem; 2017 Aug; 173():105-112. PubMed ID: 28511060
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
Mohammed MQ; Retsas S
Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
[TBL] [Abstract][Full Text] [Related]
14. Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.
Szefler B; Czeleń P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675064
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
16. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
[TBL] [Abstract][Full Text] [Related]
17. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
18. Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP.
Ceckova M; Vackova Z; Radilova H; Libra A; Buncek M; Staud F
Toxicol In Vitro; 2008 Dec; 22(8):1846-52. PubMed ID: 18801423
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
20. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory.
Kato R; Sato T; Iwamoto A; Yamazaki T; Nakashiro S; Yoshikai S; Fujimoto A; Imano H; Ijiri Y; Mino Y; Chikuma M; Tanaka K; Hayashi T
Biopharm Drug Dispos; 2019 Jul; 40(7):242-249. PubMed ID: 31219617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]